What is Syncell?
Established in 2020, Syncell operates at the intersection of advanced microscopy and proteomics. The company has developed the Microscoop platform, a specialized solution designed to facilitate microscopy-guided spatial protein purification. By integrating proprietary reagents such as Synlight and Synpull, Syncell addresses critical bottlenecks in biological research, allowing scientists to perform unbiased, deep, and spatially precise proteomic discovery. This technology fills a vital gap in the life sciences market, enabling researchers to isolate and analyze proteins from specific, visually identifiable regions of interest with unprecedented sensitivity and specificity. The company's current market position is defined by its commitment to bridging the gap between visual observation and molecular identification, providing researchers with the tools necessary to identify key protein players in complex biological systems.
How much funding has Syncell raised?
Syncell has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2024): $15M with participation from Taiwania Capital
Key Investors in Syncell
Taiwania Capital
Taiwania Capital is a venture capital firm founded in 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises, focusing on high-potential startups in sectors including AI, robotics, and next-generation semiconductors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Syncell?
With the successful closure of this major enterprise-level funding, Syncell is set to scale its R&D and production capabilities to meet increasing demand for its Microscoop Mint platform. The strategic roadmap focuses on deepening customer engagement and expanding the utility of its proprietary reagents across diverse research applications. As the company continues to refine its spatial proteomics workflow, the focus will shift toward establishing a broader commercial footprint and solidifying its role as a foundational provider in the next generation of proteomic discovery. The infusion of capital provides the necessary runway to optimize production efficiency and support the company's mission of empowering researchers to solve complex biological problems through high-precision, microscopy-guided analysis.
See full Syncell company page
